Doctor's Data is open, fully operational, and we can drop ship kits directly to patients. More updates here.

NEW: Podcast & Webinar just added to


Understanding the GI360 Stool Test: an interview with David Quig, PhD, VP of Scientific Support from Doctor's Data and Laura Stirling, Regenerus Laboratories


Interpreting and Applying GI360 Test Data: Identifying the 3 Stages of GI Dysfunction by Dan Kalish, DC and Julia Malkowski, ND, DC


NEW: Schedule a video or phone meeting now with your Doctor's Data account representative. We can assist with new account set up, test profile questions, sample report tours, pricing questions, staff education and more.


Laboratory, Endocrine, & Neurotransmitter Symposium

August 28-30, 2020

Bellevue, WA

Gain additional clinical insight and treatment considerations to evaluate some of the most prevalent and challenging conditions that patients present with, including depression, anxiety, altered mental focus and stamina, sexual dysfunction, sleep disturbances, addictions and dependencies, weight management, and chronic disease. Get notified when registration goes live!


Gastrointestinal Dysbiosis Impacts Immune Function | 4/28/2020

Melatonin: Immune-Modulating Role in COVID-19? | 4/14/2020

GUS Activity, Diet and Low IQ | 3/31/2020

HPA Axis and Immunity: Why it’s a Good Time to Modulate Stress | 3/18/2020

Best Practices for Salivary Specimen Collection | 3/3/2020

Coffee, Estrogen and Health: What’s the consensus? | 2/18/2020

Belly Fat: A dangerous place for unwanted pounds | 2/4/2020

Urinary Neurotransmitter Testing: Spot vs 24 hour collections | 1/22/2020

The Role of the Gut Microbiota in the Development of Autoimmune Diseases | 12/17/2019

Glycine: Another Tool for the Hormone and Sleep Balancing Kit | 12/04/2019

Microbiota-Gut-Brain Axis: Behavior and Dementia Implications | 11/12/2019

Estrogen and Brain Function: Mental Clarity Through Menopause | 10/29/2019

The Influence of Hormones on Hashimoto's Thyroiditis


By Fiona Campbell ND | May 12, 2020

Autoimmune diseases are widely heterogeneous, the common denominator being systemic and/or organ-specific breakdown in immunological tolerance for a person’s own tissue. Like most chronic illnesses, autoimmune diseases have multifactorial etiologies including genetic predisposition, lifestyle, viral exposure, environmental exposure, hormonal influence, and more. The prevalence of autoimmune disease in women compared to men is often examined, and the difference in hormones (specifically estrogen and progesterone) is often implicated. Approximately 80% of all autoimmune disease in the United States occurs in women, which amounts to nearly 18 million women with one or more autoimmune disease(s). The most common autoimmune thyroid disease is Hashimoto’s Thyroiditis (HT) affecting 1-2% of people in the United States. While genetic susceptibility contributes up to 80% of the pathogenesis of HT,3 hormonal factors are also at play due to their influence on the immune system. 

Given the much higher occurence of HT among women vs. men (7:1), and the association between HT and polycystic ovary syndrome (PCOS), researchers have examined the influence of hormones on HT. A study performed by Arduc, et al., published in 2015, investigates the relationship between hormonal imbalances in patients with PCOS versus control patients, measuring levels of thyroid stimulating hormone (TSH), thyroid peroxidase antibody (anti-TPO), thyroglobulin antibody (anti-Tg), estradiol, progesterone, testosterone, and other markers. The results show that PCOS patients have significantly higher levels of TSH, anti-TPO, and anti-Tg, and that among PCOS patients, estradiol levels are significantly higher in those with anti-TPO antibodies than those without. The researchers conclude that higher estradiol levels, and decreased progesterone/estradiol ratio, are directly involved in elevations of anti-TPO.1 

A 2015 review article by Gaberšček, et al., explores mechanisms of the association between PCOS and HT, examining multiple areas including genetics, thymus development, vitamin D deficiency, and hormones such as estrogen and progesterone. The article discusses the strong epidemiological evidence of hormone influence on HT, pointing out that female-to-male ratio of HT in pre-pubertal children is significantly lower than the ratio post-puberty, after females have increased production of estrogen and progesterone. The immune effects of estrogen and progesterone are explored: estrogens decrease activity of T suppressor cells, increase activity of B cells, and increase the secretion IL-6, all contributing to autoimmunity in HT, while progesterone decreases IL-6 and decreases peripheral antibody production. In the case of PCOS, progesterone status is typically low due to anovulatory cycles. The authors conclude that imbalances in estrogen and progesterone (a low progesterone/estradiol ratio), may promote the development of HT in these patients, resulting from the immune-stimulating effects of unbalanced estrogen.2 

While the aforementioned study and review article examine HT and hormones in the context of PCOS, it is reasonable to consider the potential effects of a decreased progesterone/estradiol ratio on the risk for, or exacerbation of, HT in non-PCOS women as well. Salivary hormone profiles that include estradiol and progesterone, and the progesterone to estradiol ratio, are a consideration for patients with HT, PCOS, or those at high risk for either disorder. 


1. Arduc A, Aycicek dogan B, Bilmez S, et al. High prevalence of Hashimoto's thyroiditis in patients with polycystic ovary syndrome: does the imbalance between estradiol and progesterone play a role?. Endocr Res. 2015;40(4):204-10. 

2. Gaberšček S, Zaletel K, Schwetz V, Pieber T, Obermayer-pietsch B, Lerchbaum E. Mechanisms in endocrinology: thyroid and polycystic ovary syndrome. Eur J Endocrinol. 2015;172(1):R9-21. 

3. Wiersinga WM. Clinical Relevance of Environmental Factors in the Pathogenesis of Autoimmune Thyroid Disease. Endocrinol Metab (Seoul). 2016;31(2):213-22.


Brain Aging in the Menopausal Woman: Effects on Moods, Memory and Botanical Solutions

by Tori Hudson, ND | May 19, 2020 at 1 PM PST

The aging brain in perimenopausal and postmenopausal women comes with metabolic changes, neurotransmitter changes, vascular changes and more. All of these changes contribute to the unique role of hormones in moods and memory. Select botanicals have some very important impacts and implications in these changes and have a clinical role in prevention and management. To be discussed: Bacopa, saffron, curcumin, St. John's wort, gotu kola, lemon balm, rhodiola.


1) Provide an overview of the brain changes in peri and postmenopausal women

2) Provide an overview of the ramifications of these changes in terms of mood and cognition

3) Instruct attendees on uses of select herbs for these clinical manifestations including efficacy, safety, indications, contraindications and dosages

A live Q&A will follow the presentation.

Wellness Wednesday Webinar Series

Neurotransmitter Primer

By: Fiona Campbell, ND | June 3rd, 2020

In this month's webinar, you will review the anatomy and physiology of neurotransmitter (NT) secretion and function, Examine the role of individual NTs and how imbalances present clinically, and Learn to incorporate NT evaluation and treatment in your hormone balancing practice. Attendees will also be treated to treatment considerations for addressing neurotransmitter imbalances, without prescription medications. Sign up today!

Disclaimer: All information given about health conditions, treatment, products, and dosages are for educational purposes only and do not constitute medical advice.